<DOC>
	<DOCNO>NCT00552422</DOCNO>
	<brief_summary>The purpose study examine clinical response domperidone solid organ transplant recipient gastroparesis .</brief_summary>
	<brief_title>Domperidone Gastroparesis Solid Organ Transplantation</brief_title>
	<detailed_description>After heart lung transplantation , stomach tend empty much slow normal . This slow emptying call `` gastroparesis . '' Gastroparesis uncomfortable often lead nausea vomit . In addition drastically impact quality life , severe nausea vomit also lead malnutrition inability take oral medication , contribute complication transplantation . Treatments gastroparesis include medical surgical therapy work patient . Domperidone peripheral D2 antagonist improve empty stomach patient gastroparesis . Domperidone FDA approve time . Some patient develop lifethreatening abnormal heart rhythm receive domperidone intravenously . This problem see domperidone give mouth . We propose administer domperidone mouth standard dos solid organ transplant patient gastroparesis responsive standard medical therapy experience adverse drug side effect . This study blind ( open-label ) single treatment arm ( control placebo group ) .</detailed_description>
	<mesh_term>Gastroesophageal Reflux</mesh_term>
	<mesh_term>Gastroparesis</mesh_term>
	<mesh_term>Domperidone</mesh_term>
	<criteria>gastroparesis gastroesophageal reflux refractory standard therapy . sign informed consent serious cardiac arrhythmia clinically significant bradycardia , sinus node dysfunction , heart block . prolong QTc clinically significant electrolyte disorder . gastrointestinal hemorrhage obstruction . prolactinoma pregnant breast feed female know allergy domperidone .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2015</verification_date>
	<keyword>gastroparesis</keyword>
	<keyword>gastroesophageal reflux</keyword>
</DOC>